Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10070)
All Articles published online
|
Publishing Process of This Article
|
Dec 10, 2014 (publication date) through Jul 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Milani A, Geuna E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World J Clin Oncol 2014; 5(5): 990-1001 [PMID: 25493235 DOI: 10.5306/wjco.v5.i5.990] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v5/i5/990.htm |
| Number | Citing Articles |
| 1 |
Miguel Martin, Jose A Garcia-Saenz, Luis Manso, Antonio Llombart, Alejo Cassinello, Manuel Atienza, Francois Ringeisen, Eva Ciruelos. Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer. Future Oncology 2020; 16(33): 2763 doi: 10.2217/fon-2020-0604
|
| 2 |
Ana Carolina Pavanelli, Flavia Rotea Mangone, Luciana R. C. Barros, Juliana Machado-Rugolo, Vera L. Capelozzi, Maria A. Nagai. Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer. Genes 2021; 12(7): 996 doi: 10.3390/genes12070996
|
| 3 |
Flavia Jacobs, Elisa Agostinetto, Alessandra Solferino, Rosalba Torrisi, Giovanna Masci, Armando Santoro, Rita De Sanctis. Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib. Journal of Clinical Medicine 2023; 12(5): 1775 doi: 10.3390/jcm12051775
|
| 4 |
Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Takashi Nagasawa, Yoshiko Umeyama, Masakazu Toi. Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study. Cancer Science 2018; 109(3): 803 doi: 10.1111/cas.13507
|
| 5 |
Yu-Ming Hua. An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer. Archives of Gynecology and Obstetrics 2019; 300(5): 1377 doi: 10.1007/s00404-019-05304-8
|
| 6 |
Nicholas B. Figura, Thrisha K. Potluri, Homan Mohammadi, Daniel E. Oliver, John A. Arrington, Timothy J. Robinson, Arnold B. Etame, Nam D. Tran, James K. Liu, Hatem Soliman, Peter A. Forsyth, Solmaz Sahebjam, H. Michael Yu, Hyo S. Han, Kamran A. Ahmed. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. Journal of Neuro-Oncology 2019; 144(3): 583 doi: 10.1007/s11060-019-03260-6
|
| 7 |
Jia-jie Shi, Si-meng Chen, Chen-liang Guo, Yi-xue Li, Jian Ding, Ling-hua Meng. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. Acta Pharmacologica Sinica 2018; 39(8): 1338 doi: 10.1038/aps.2017.181
|
| 8 |
Endi Kripa, Veronica Rizzo, Francesca Galati, Giuliana Moffa, Federica Cicciarelli, Carlo Catalano, Federica Pediconi. Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.987012
|
| 9 |
Kallirroi Voudouri, Dragana Nikitovic, Aikaterini Berdiaki, Dimitris Kletsas, Nikos K. Karamanos, George N. Tzanakakis. IGF-I/EGF and E2 signaling crosstalk through IGF-IR conduit point affects breast cancer cell adhesion. Matrix Biology 2016; 56: 95 doi: 10.1016/j.matbio.2016.06.005
|
| 10 |
Nan Zheng, Lu Liu, Weiwei Liu, Ping Zhang, Huai Huang, Linghe Zang, Toshihiko Hayashi, Shin-ichi Tashiro, Satoshi Onodera, Mingyu Xia, Takashi Ikejima. ERβ up-regulation was involved in silibinin-induced growth inhibition of human breast cancer MCF-7 cells. Archives of Biochemistry and Biophysics 2016; 591: 141 doi: 10.1016/j.abb.2016.01.002
|
| 11 |
Paolo Pronzato. Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. Future Oncology 2017; 13(16): 1371 doi: 10.2217/fon-2017-0098
|
| 12 |
Chun-Yu Liu, Chia-Yun Wu, Karineh Petrossian, Tzu-Ting Huang, Ling-Ming Tseng, Shiuan Chen. Treatment for the endocrine resistant breast cancer: Current options and future perspectives. The Journal of Steroid Biochemistry and Molecular Biology 2017; 172: 166 doi: 10.1016/j.jsbmb.2017.07.001
|
| 13 |
Kenji Tamura, Hirofumi Mukai, Yoichi Naito, Kan Yonemori, Makoto Kodaira, Yuko Tanabe, Noboru Yamamoto, Shozo Osera, Masaoki Sasaki, Yuko Mori, Satoshi Hashigaki, Takashi Nagasawa, Yoshiko Umeyama, Takayuki Yoshino. Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Science 2016; 107(6): 755 doi: 10.1111/cas.12932
|
| 14 |
Wenting Song, Qian S. Liu, Zhendong Sun, Xiaoxi Yang, Qunfang Zhou, Guibin Jiang. Polyfluorinated iodine alkanes regulated distinct breast cancer cell progression through binding with estrogen receptor alpha or beta isoforms. Environmental Pollution 2018; 239: 300 doi: 10.1016/j.envpol.2018.04.037
|
| 15 |
Simone U. Dalm, Anieta M. Sieuwerts, Maxime P. Look, Marleen Melis, Carolien H.M. van Deurzen, John A. Foekens, Marion de Jong, John W.M. Martens. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy. Journal of Nuclear Medicine 2015; 56(10): 1487 doi: 10.2967/jnumed.115.160739
|
| 16 |
George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. Smith, Nawel Bourayou, Antonio Llombart-Cussac. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology 2017; 35(25): 2875 doi: 10.1200/JCO.2017.73.7585
|
| 17 |
Hitisha K. Patel, Teeru Bihani. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics 2018; 186: 1 doi: 10.1016/j.pharmthera.2017.12.012
|
| 18 |
Nikolas Hörmann, Christina Kalchschmid, Patricia Grabher, Isabella Grassmayr, Paul Kapitza, Teresa Kaserer, Ronald Gust. Development of heterodimeric estrogen receptor alpha antagonists to target simultaneously the ligand and coactivator binding site. Archiv der Pharmazie 2023; 356(7) doi: 10.1002/ardp.202200638
|
| 19 |
Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Antonio Marra, Angela Esposito, Marzia Adelia Locatelli, Dario Trapani, Carlo Pescia, Nicola Fusco, Giuseppe Curigliano, Carmen Criscitiello. The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility. Critical Reviews in Oncology/Hematology 2023; 192: 104148 doi: 10.1016/j.critrevonc.2023.104148
|
| 20 |
Daniella Klebaner, Stephen Hamilton-Dutoit, Thomas Ahern, Anatasha Crawford, Thomas Jakobsen, Deirdre P. Cronin-Fenton, Per Damkier, Emiel Janssen, Anders Kjaersgaard, Anne Gulbech Ording, Håvard Søiland, Henrik Toft Sørensen, Timothy L. Lash, Ylva Hellberg, Pirkko L. Härkönen. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. PLOS ONE 2017; 12(3): e0171453 doi: 10.1371/journal.pone.0171453
|
| 21 |
Panpan Wang, Xiaobo Xu, Yinghong Li, Bo Li, Qinglan Pei, Pei Yu, Chenxi Jing, Meng Lu. Discovery of Novel Mammalian target of rapamycin (mTOR) Inhibitors by Support Vector Machine. IOP Conference Series: Earth and Environmental Science 2021; 692(3): 032028 doi: 10.1088/1755-1315/692/3/032028
|
| 22 |
Edith A. Perez. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resistance Updates 2016; 24: 13 doi: 10.1016/j.drup.2015.11.001
|
| 23 |
Tommaso De Marchi, Ning Qing Liu, Cristoph Stingl, Mieke A. Timmermans, Marcel Smid, Maxime P. Look, Mila Tjoa, Rene B.H. Braakman, Mark Opdam, Sabine C. Linn, Fred C.G.J. Sweep, Paul N. Span, Mike Kliffen, Theo M. Luider, John A. Foekens, John W.M. Martens, Arzu Umar. 4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology 2016; 10(1): 24 doi: 10.1016/j.molonc.2015.07.004
|
| 24 |
A. Davie, G. Cuyun Carter, A. Rider, A. Bailey, K. Lewis, G. Price, H. Ostojic, F. Ringeisen, X. Pivot. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study. ESMO Open 2021; 6(4): 100226 doi: 10.1016/j.esmoop.2021.100226
|
| 25 |
Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen, Zhiyang Li. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11322-2
|
| 26 |
Annie Guérin, Yanni Hao, Derek Tang, Miranda Peeples, Anna Fang, Andrew Kageleiry, Valerie Koo, Nanxin Li, Eric Q. Wu. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opinion on Pharmacotherapy 2016; 17(9): 1189 doi: 10.1080/14656566.2016.1176148
|
| 27 |
Gloria Mittica, Sofia Genta, Massimo Aglietta, Giorgio Valabrega. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. International Journal of Molecular Sciences 2016; 17(7): 1169 doi: 10.3390/ijms17071169
|
| 28 |
Fazal I. Raziq. Abemaciclib-Associated Status Epilepticus. American Journal of Therapeutics 2022; 29(6): e772 doi: 10.1097/MJT.0000000000001179
|
| 29 |
Abbas Mohammed Ali, Wei Wang, Qiu-Yun Chen. Structure and biomolecular recognition of nitro-BODIPY-andrographolide assembles for cancer treatment. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2021; 263: 120180 doi: 10.1016/j.saa.2021.120180
|
| 30 |
Mei-Yin C. Polley, Maura N. Dickler, Jason Sinnwell, Kathleen Tenner, Juan de la Haba, Sibylle Loibl, Matthew P. Goetz, Jonas Bergh, John Roberston, Fergus Couch, Matthew J. Ellis, Miguel Martin. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment 2021; 189(1): 15 doi: 10.1007/s10549-021-06319-z
|
| 31 |
Jürgen Dittmer. Nuclear Mechanisms Involved in Endocrine Resistance. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.736597
|
| 32 |
Lenka Ilkovičová, Nina Trošt, Erika Szentpéteriová, Peter Solár, Radovan Komel, Nataša Debeljak. Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen. International Journal of Oncology 2017; 51(2): 737 doi: 10.3892/ijo.2017.4061
|
| 33 |
Siqi Liu, Xin Sun, Xiaohui Xu, Fangcai Lin. Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis. Journal of Breast Cancer 2020; 23(5): 460 doi: 10.4048/jbc.2020.23.e55
|
| 34 |
Chisako Izumi, Kiyoshi Misawa, Shiori Endo, Kenichi Sugiyama, Daiki Mochizuki, Atsushi Imai, Masato Mima, Yuki Misawa, Takashi Yamatodani, Hiroyuki Mineta. Late recurrence of breast carcinoma metastasis to the hypopharynx: a case report. SpringerPlus 2016; 5(1) doi: 10.1186/s40064-016-2226-1
|
| 35 |
Berry Button, Ben Ho Park. ESR1 mutations: Pièce de résistance. Genes & Diseases 2016; 3(2): 124 doi: 10.1016/j.gendis.2016.03.005
|
| 36 |
Svetlana E. Semina, Alexander M. Scherbakov, Anna A. Vnukova, Dmitry V. Bagrov, Evgeniy G. Evtushenko, Vera M. Safronova, Daria A. Golovina, Ludmila N. Lyubchenko, Margarita V. Gudkova, Mikhail A. Krasil’nikov. Exosome-Mediated Transfer of Cancer Cell Resistance to Antiestrogen Drugs. Molecules 2018; 23(4): 829 doi: 10.3390/molecules23040829
|
| 37 |
Jinyao Huang, Liang Zheng, Zicheng Sun, Jie Li. CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review). International Journal of Molecular Medicine 2022; 50(4) doi: 10.3892/ijmm.2022.5184
|
| 38 |
Roudy Chiminch Ekyalongo, Douglas Yee. Revisiting the IGF-1R as a breast cancer target. npj Precision Oncology 2017; 1(1) doi: 10.1038/s41698-017-0017-y
|
| 39 |
Tuğba Önder, Öztürk Ateş, İrem Öner, Cengiz Karaçin. Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors. Clinical Breast Cancer 2024; 24(6): 519 doi: 10.1016/j.clbc.2024.05.004
|
| 40 |
C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs 2021; 81(3): 317 doi: 10.1007/s40265-020-01461-2
|
| 41 |
Masakazu Toi, Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Joohyuk Sohn, In Hae Park, Seock‐Ah Im, Shin‐Cheh Chen, Sotaro Enatsu, P. Kellie Turner, Valérie A. M. André, Molly C. Hardebeck, Sachi Sakaguchi, Matthew P. Goetz, George W. Sledge. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials. Cancer Science 2021; 112(6): 2381 doi: 10.1111/cas.14877
|
| 42 |
Jennifer L. Brown, Christina S. Chu. Gynecological Cancers. 2016; : 99 doi: 10.1007/978-3-319-32907-9_6
|
| 43 |
Ying Zhou, Jinmei Zhou, Jinyi Xiao, Yuehua Wang, Hao Wang, Haoyuan Shi, Chunyan Yue, Fei Jia, Ping Li, Zhiyuan Hu, Yanlian Yang, Zefei Jiang, Tao Wang. Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.866293
|
| 44 |
Yan Xiu Ouyang, Jun Feng, Zun Wang, Guo Jun Zhang, Min Chen. miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα. Molecular Biomedicine 2021; 2(1) doi: 10.1186/s43556-021-00045-0
|
| 45 |
Lijuan Lyu, Meng Wang, Yi Zheng, Tian Tian, Yujiao Deng, Peng Xu, Shuai Lin, Si Yang, Linghui Zhou, Qian Hao, Ying Wu, Zhijun Dai, Huafeng Kang. <p>Overexpression of <em>FAM234B</em> Predicts Poor Prognosis in Patients with Luminal Breast Cancer</p>. Cancer Management and Research 2020; : 12457 doi: 10.2147/CMAR.S280009
|
| 46 |
Euphemia Y. Leung, Marjan E. Askarian-Amiri, Debina Sarkar, Carole Ferraro-Peyret, Wayne R. Joseph, Graeme J. Finlay, Bruce C. Baguley. Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. Frontiers in Oncology 2017; 7 doi: 10.3389/fonc.2017.00184
|
| 47 |
George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart-Cussac. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2. JAMA Oncology 2020; 6(1): 116 doi: 10.1001/jamaoncol.2019.4782
|
| 48 |
Olga E. Andreeva, Danila V. Sorokin, Ekaterina I. Mikhaevich, Irina V. Bure, Yuri Y. Shchegolev, Marina V. Nemtsova, Margarita V. Gudkova, Alexander M. Scherbakov, Mikhail A. Krasil’nikov. Towards Unravelling the Role of ERα-Targeting miRNAs in the Exosome-Mediated Transferring of the Hormone Resistance. Molecules 2021; 26(21): 6661 doi: 10.3390/molecules26216661
|
| 49 |
Karla A Lee, Scott TC Shepherd, Stephen RD Johnston. Abemaciclib, a Potent Cyclin-Dependent Kinase 4 and 6 Inhibitor, for Treatment of ER-Positive Metastatic Breast Cancer. Future Oncology 2019; 15(29): 3309 doi: 10.2217/fon-2019-0169
|
| 50 |
Hany A Abdel-Hafiz, Kathryn B Horwitz. Role of Epigenetic Modifications in Luminal Breast Cancer. Epigenomics 2015; 7(5): 847 doi: 10.2217/epi.15.10
|
| 51 |
Stephen Johnston, Miguel Martin, Angelo Di Leo, Seock-Ah Im, Ahmad Awada, Tammy Forrester, Martin Frenzel, Molly C. Hardebeck, Joanne Cox, Susana Barriga, Masakazu Toi, Hiroji Iwata, Matthew P. Goetz. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer 2019; 5(1) doi: 10.1038/s41523-018-0097-z
|
| 52 |
Shashank Chaturvedi, Anuj Garg. A comprehensive review on novel delivery approaches for exemestane. Journal of Drug Delivery Science and Technology 2022; 75: 103655 doi: 10.1016/j.jddst.2022.103655
|
| 53 |
Tianzhuo Wang, Guoshuang Shen, Jinming Li, Xingfa Huo, Miaozhou Wang, Zhen Liu, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao. Second-line Endocrine Therapy of Hormone Receptor-positive/HER2-
negative Advanced Breast Cancer: A Systematic Review and Network
Meta-analysis. Current Cancer Drug Targets 2023; 23(9): 718 doi: 10.2174/1568009623666230407101128
|
| 54 |
Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Masato Takahashi, Yoshinori Ito, Yasuo Miyoshi, Takahiro Nakayama, Hirofumi Mukai, Jan-Stefan van der Walt, Joji Mori, Sachi Sakaguchi, Tsutomu Kawaguchi, Yoshinori Tanizawa, Antonio Llombart-Cussac, George W. Sledge, Masakazu Toi. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer 2021; 28(5): 1038 doi: 10.1007/s12282-021-01239-8
|
| 55 |
Sarah A. El-Lakany, Nazik A. Elgindy, Maged W. Helmy, Marwa M Abu-Serie, Ahmed O. Elzoghby. Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer. Expert Opinion on Drug Delivery 2018; 15(9): 835 doi: 10.1080/17425247.2018.1505858
|
| 56 |
Daniel Gabriel Pons, Margalida Torrens-Mas, Mercedes Nadal-Serrano, Jorge Sastre-Serra, Pilar Roca, Jordi Oliver. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents. The International Journal of Biochemistry & Cell Biology 2015; 66: 85 doi: 10.1016/j.biocel.2015.07.014
|
| 57 |
Xi Zhang, Nadia Harbeck, Udo Jeschke, Sophie Doisneau-Sixou. Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. Journal of Cancer Research and Clinical Oncology 2017; 143(7): 1107 doi: 10.1007/s00432-016-2325-y
|
| 58 |
Thomas Ho Lai Yau, Kwok-Leung Cheung. Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocrine-Related Cancer 2018; 25(7): 705 doi: 10.1530/ERC-18-0021
|
| 59 |
Gayathri Nagaraj, Cynthia X. Ma. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. Advances in Therapy 2021; 38(1): 109 doi: 10.1007/s12325-020-01552-2
|
| 60 |
Paola Griseri, Ornella Garrone, Alessandra Lo Sardo, Martino Monteverde, Marta Rusmini, Federica Tonissi, Marco Merlano, Paolo Bruzzi, Cristiana Lo Nigro, Isabella Ceccherini. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients. Oncotarget 2016; 7(18): 26465 doi: 10.18632/oncotarget.8417
|
| 61 |
Marie Robert, Jean-Sébastien Frenel, Emmanuelle Bourbouloux, Dominique Berton Rigaud, Anne Patsouris, Paule Augereau, Carole Gourmelon, Mario Campone. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology 2019; 15(2): 85 doi: 10.1080/17425255.2019.1559816
|
| 62 |
Adam M. Brufsky, Maura N. Dickler. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. The Oncologist 2018; 23(5): 528 doi: 10.1634/theoncologist.2017-0423
|
| 63 |
Zhanglin Lin Cui, Zbigniew Kadziola, Ilya Lipkovich, Douglas E Faries, Kristin M Sheffield, Gebra Cuyun Carter. Predicting optimal treatment regimens for patients with HR+/HER2- breast cancer using machine learning based on electronic health records. Journal of Comparative Effectiveness Research 2021; 10(9): 777 doi: 10.2217/cer-2020-0230
|
| 64 |
Dandan Xia, Huiyu Wang, Runjie Wang, Chaoying Liu, Junying Xu. High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney. Medicine 2018; 97(24): e11115 doi: 10.1097/MD.0000000000011115
|
| 65 |
Vassilis Aggelis, Stephen R. D. Johnston. Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs 2019; 79(17): 1849 doi: 10.1007/s40265-019-01208-8
|
| 66 |
Jing-Pei Long, Xiao-Na Li, Feng Zhang. Targeting metabolism in breast cancer: How far we can go?. World Journal of Clinical Oncology 2016; 7(1): 122-130 doi: 10.5306/wjco.v7.i1.122
|
| 67 |
Qiang Wang, Xia Du, Bingjie Zhou, Jing Li, Wenlong Lu, Qiuyun Chen, Jing Gao. Mitochondrial dysfunction is responsible for fatty acid synthase inhibition-induced apoptosis in breast cancer cells by PdpaMn. Biomedicine & Pharmacotherapy 2017; 96: 396 doi: 10.1016/j.biopha.2017.10.008
|
| 68 |
Yongyan Li, Li Li, Qi Du, Yongfu Li, Haifang Yang, Qin Li. Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2− ABC Patients: A Systematic Review and Meta-Analysis. Cancer Investigation 2021; 39(5): 369 doi: 10.1080/07357907.2021.1910705
|
| 69 |
Angelo Di Leo, Joyce O’Shaughnessy, George W. Sledge, Miguel Martin, Yong Lin, Martin Frenzel, Molly C. Hardebeck, Ian C. Smith, Antonio Llombart-Cussac, Matthew P. Goetz, Stephen Johnston. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. npj Breast Cancer 2018; 4(1) doi: 10.1038/s41523-018-0094-2
|
| 70 |
Kallirroi Voudouri, Aikaterini Berdiaki, Maria Tzardi, George N. Tzanakakis, Dragana Nikitovic. Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease. Analytical Cellular Pathology 2015; 2015: 1 doi: 10.1155/2015/975495
|
| 71 |
Matthew P. Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso, Orit C. Freedman, Georgina Garnica Jaliffe, Tammy Forrester, Martin Frenzel, Susana Barriga, Ian C. Smith, Nawel Bourayou, Angelo Di Leo. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology 2017; 35(32): 3638 doi: 10.1200/JCO.2017.75.6155
|
| 72 |
Ning Xie, Tao Qin, Wei Ren, Herui Yao, Yunfang Yu, Huangming Hong. <p>Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer</p>. Cancer Management and Research 2020; : 4241 doi: 10.2147/CMAR.S254365
|
| 73 |
Amruta Ronghe, Anwesha Chatterjee, Bhupendra Singh, Prasad Dandawate, Fatma Abdalla, Nimee K. Bhat, Subhash Padhye, Hari K. Bhat. 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors α and β in breast cancer cells. Toxicology and Applied Pharmacology 2016; 301: 1 doi: 10.1016/j.taap.2016.03.003
|
| 74 |
Adam M. Brufsky. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treatment Reviews 2017; 59: 22 doi: 10.1016/j.ctrv.2017.06.004
|
| 75 |
Emily A. Bossart, Nilgun Tasdemir, Matthew J. Sikora, Amir Bahreini, Kevin M. Levine, Jian Chen, Ahmed Basudan, Britta M. Jacobsen, Timothy F. Burns, Steffi Oesterreich. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Research and Treatment 2019; 175(2): 327 doi: 10.1007/s10549-019-05161-8
|
| 76 |
A. van Ommen-Nijhof, I. R. Konings, C. J. J. van Zeijl, C. A. Uyl-de Groot, V. van der Noort, A. Jager, G. S. Sonke. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4978-1
|
| 77 |
Iulia Dude, Zhengxing Zhang, Julie Rousseau, Navjit Hundal-Jabal, Nadine Colpo, Helen Merkens, Kuo-Shyan Lin, François Bénard. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharmacy and Chemistry 2017; 2(1) doi: 10.1186/s41181-017-0023-y
|
| 78 |
Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-60101-x
|